What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

Assessment of coagulation potential of concomitant factor VIII administration in patients with haemophilia a receiving emicizumab prophylaxis (CAGUYAMA Study): A multicenter, open-label, non-randomized clinical trial

View Full Paper

Ask AI

Bookmark

Change in maximum coagulation rate was observed with FVIII administration, reaching effective hemostasis in patients.
In a multicenter clinical trial with 100 hemophilia A patients, the study demonstrated significant improvements in coagulation.
Thrombin generation assays indicated increased peak thrombin levels post-FVIII administration, providing critical evaluation of hemostasis.
Findings support clinical management strategies that incorporate both emicizumab and factor VIII for bleeding events.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical trial assesses coagulation function from factor VIII in hemophilia A patients receiving emicizumab, suggesting effective management for bleeding.

Cite This Study

Ogiwara et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e114 https://doi.org/10.1182/blood-2025-4847

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial assesses coagulation function from factor VIII in hemophilia A patients receiving emicizumab, suggesting effective management for bleeding.

Assessment of coagulation potential of concomitant factor VIII administration in patients with haemophilia a receiving emicizumab prophylaxis (CAGUYAMA Study): A multicenter, open-label, non-randomized clinical trial

Key Points

Discussion

Implication

Cite This Study

Assessment of coagulation potential of concomitant factor VIII administration in patients with haemophilia a receiving emicizumab prophylaxis (CAGUYAMA Study): A multicenter, open-label, non-randomized clinical trial

Key Points

Discussion

Implication

Cite This Study